These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 26289787)

  • 21. Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies.
    Avila J; Pallas N; Bolós M; Sayas CL; Hernandez F
    Expert Opin Ther Targets; 2016 Jun; 20(6):653-61. PubMed ID: 26652296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs.
    Lozupone M; Solfrizzi V; D'Urso F; Di Gioia I; Sardone R; Dibello V; Stallone R; Liguori A; Ciritella C; Daniele A; Bellomo A; Seripa D; Panza F
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):319-335. PubMed ID: 32772738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease.
    Marcus JN; Schachter J
    J Neurogenet; 2011 Dec; 25(4):127-33. PubMed ID: 22091726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New perspectives on the role of tau in Alzheimer's disease. Implications for therapy.
    Medina M; Avila J
    Biochem Pharmacol; 2014 Apr; 88(4):540-7. PubMed ID: 24462919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease.
    Wischik CM; Staff RT; Wischik DJ; Bentham P; Murray AD; Storey JM; Kook KA; Harrington CR
    J Alzheimers Dis; 2015; 44(2):705-20. PubMed ID: 25550228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic targets in Alzheimer's disease and related tauopathies.
    Corbo CP; Alonso Adel C
    Prog Mol Biol Transl Sci; 2011; 98():47-83. PubMed ID: 21199770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic approaches for Alzheimer's disease.
    Jahnke U
    IDrugs; 2008 Jan; 11(1):4-6. PubMed ID: 18175250
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunotherapeutic approaches for Alzheimer's disease.
    Wisniewski T; Goñi F
    Neuron; 2015 Mar; 85(6):1162-76. PubMed ID: 25789753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease.
    Iqbal K; Gong CX; Liu F
    Expert Opin Ther Targets; 2014 Mar; 18(3):307-18. PubMed ID: 24387228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
    Li Y; Liu Y; Wang Z; Jiang Y
    Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacology of novel anti-Alzheimer disease modifying medications.
    Caraci F; Bosco P; Leggio GM; Malaguarnera M; Drago F; Bucolo C; Salomone S
    Curr Top Med Chem; 2013; 13(15):1853-63. PubMed ID: 23931438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.
    Seripa D; Solfrizzi V; Imbimbo BP; Daniele A; Santamato A; Lozupone M; Zuliani G; Greco A; Logroscino G; Panza F
    Expert Rev Neurother; 2016; 16(3):259-77. PubMed ID: 26822031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of WO2011045166A1, Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction.
    Zheng F; Zhang B; Sun Y; Qiu M; Su J
    Expert Opin Ther Pat; 2015 Jul; 25(7):831-5. PubMed ID: 25945965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
    Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
    J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CHI's Eighth Annual World Pharmaceutical Congress. Targeting Alzheimer's with novel therapeutics: Part 2.
    Yan R
    IDrugs; 2009 Aug; 12(8):482-4. PubMed ID: 19629880
    [No Abstract]   [Full Text] [Related]  

  • 36. Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):683-695. PubMed ID: 28490260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tau immunotherapy for Alzheimer's disease.
    Pedersen JT; Sigurdsson EM
    Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigational drugs for the treatment of cervical cancer.
    Barra F; Lorusso D; Leone Roberti Maggiore U; Ditto A; Bogani G; Raspagliesi F; Ferrero S
    Expert Opin Investig Drugs; 2017 Apr; 26(4):389-402. PubMed ID: 28274154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting Hsp90 and its co-chaperones to treat Alzheimer's disease.
    Blair LJ; Sabbagh JJ; Dickey CA
    Expert Opin Ther Targets; 2014 Oct; 18(10):1219-32. PubMed ID: 25069659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force.
    Cummings J; Blennow K; Johnson K; Keeley M; Bateman RJ; Molinuevo JL; Touchon J; Aisen P; Vellas B
    J Prev Alzheimers Dis; 2019; 6(3):157-163. PubMed ID: 31062825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.